J.P. Morgan analyst Chris Schott maintains $AbbVie (ABBV.US)$ with a buy rating, and adjusts the target price from $210 to $200.
According to TipRanks data, the analyst has a success rate of 50.0% and a total average return of 1.4% over the past year.
Furthermore, according to the comprehensive report, the opinions of $AbbVie (ABBV.US)$'s main analysts recently are as follows:
The unexpected negative update on emraclidine's Phase 2 outcomes has led to its removal from revenue models, subsequently increasing the projections for Cobenfy's performance. Despite the adjustments, the long-term growth trajectory in terms of revenue and earnings per share is not anticipated to be significantly altered for the involved companies.
Analysts noted that the key Phase 2 data for AbbVie's emraclidine did not meet expectations, failing to show a statistically significant alteration from the baseline in the primary scale used to measure efficacy in schizophrenia studies. This outcome was contrary to forecasts, especially considering the drug was a central component of AbbVie's multi-billion-dollar acquisition and was anticipated to generate substantial sales towards the decade's end, potentially rivaling competitive products.
The anticipated outcomes of the EMPOWER 1 and 2 Emraclidine Phase 2 studies in Schizophrenia did not meet expectations, with placebo results surpassing those of the active arms in both trials. This has led to the realization that the primary value proposition of the significant acquisition is no longer viable.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
摩根大通分析師Chris Schott維持$艾伯維公司 (ABBV.US)$買入評級，並將目標價從210美元下調至200美元。
根據TipRanks數據顯示，該分析師近一年總勝率為50.0%，總平均回報率為1.4%。
此外，綜合報道，$艾伯維公司 (ABBV.US)$近期主要分析師觀點如下：
對emraclidine的2期結果出現意外負面更新導致其從收入模型中移除，進而提高了Cobenfy的表現預期。儘管有調整，但對於相關公司的營業收入和每股收益的長期增長軌跡預計不會受到重大改變。
分析師指出，艾伯維公司emraclidine的關鍵2期數據未達到預期，未能顯示在用於評估精神分裂症研究中療效的主要指標基線上出現顯著變化。這一結果與預測相反，尤其考慮到這種藥物是艾伯維數十億美元收購的核心組成部分，預計能在本十年末產生大量銷售，有望與競爭產品相抗衡。
在精神分裂症的EMPOWER 1和2期Emraclidine研究的預期結果未達到預期，安慰劑結果在兩項試驗中均超過活性藥物組。這導致人們意識到這一重要收購的主要價值主張已不再可行。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
